Comparison of efficacy between triamcinolone acetonide and triamcinolone hexacetonide for intraarticular therapy in juvenile idiopathic arthritis: a retrospective analysis
Open Access
- 31 March 2022
- journal article
- research article
- Published by Springer Nature in BMC Rheumatology
- Vol. 6 (1) , 1-7
Abstract
Background: There are many FDA-approved corticosteroid preparations available for intra-articular injection, however triamcinolone hexacetonide is not one of them. It was the intraarticular drug of choice among pediatric rheumatologists up until approximately a decade ago, when production of this medication ceased. It can be obtained in the United States and Canada via importation from Europe, but it is not FDA-approved at this time. We wish to compare the duration of remission of intraarticular triamcinolone hexacetonide (TH) with that of triamcinolone acetonide (TA) in children with juvenile idiopathic arthritis (JIA) and demonstrate its safety in this population. Methods: This retrospective chart review included 39 patients with JIA who received intraarticular corticosteroid injections (IACIs) from September 2018 to September 2019. These patients were reviewed and their life-time injections with either TH (41 joints) or TA (124 joints) was noted through May 30, 2021. Patients with concomitant systemic therapy initiation were excluded. The primary outcome was time to relapse. Relapse was defined by the presence of arthritis on physical examination by an attending rheumatologist. Kaplan–Meier curves and a log-rank test were constructed to compare the probability of time to relapse between IACI injections. Additionally, mixed effects cox regression models were constructed to account for multiple injections per participant. Results: Kaplan–Meier estimator of median relapse time in months was higher for TH. Based on the log-rank test, TA joints had a higher probability of experiencing a relapse during the study time (p value < 0.001). The hazard of time to relapse was reduced when comparing TH to TA in both unadjusted and adjusted mixed effects cox regression models [unadjusted hazard ratio (95% confidence interval): 0.184 (0.089, 0.381); adjusted hazard ratio (95% confidence interval): 0.189 (0.092, 0.386)]. Conclusions: TH has longer duration of action than TA and is associated with less systemic side effects. It should be considered the drug of choice for intraarticular corticosteroid injections in children with JIA.Keywords
All Related Versions
This publication has 25 references indexed in Scilit:
- Factors Influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritisEuropean Journal of Pediatrics, 2007
- Intraarticular glucocorticoid treatment reduces inflammation in synovial cell infiltrations more efficiently than in synovial blood vesselsArthritis & Rheumatism, 2005
- Triamcinolone acetonide and hexacetonide intra-articular treatment of symmetrical joints in juvenile idiopathic arthritis: a double-blind trialRheumatology, 2004
- Comparison of intra-articular triamcinolone hexacetonide and triamcinolone acetonide in oligoarticular juvenile idiopathic arthritisRheumatology, 2003
- Intra-articular corticosteroid injections in juvenile idiopathic arthritisArchives of Disease in Childhood, 2003
- Intraarticular corticosteroids for chronic arthritis in children: Efficacy and effects on cartilage and growthThe Journal of Pediatrics, 1995
- A RANDOMIZED CONTROLLED STUDY OF POST-INJECTION REST FOLLOWING INTRA-ARTICULAR STEROID THERAPY FOR KNEE SYNOVITISRheumatology, 1994
- Intra‐articular glucocorticoids in early juvenile chronic arthritisActa Paediatrica, 1993
- Triamcinolone hexacetonide versus betamethasone: A double-blind comparative study of the long-term effects of intraarticular steroids in patients with juvenile chronic arthritisScandinavian Journal of Rheumatology, 1988
- Intraarticular triamcinolone hexacetonide in the management of chronic arthritis in childrenArthritis & Rheumatism, 1986